Comprehensive Analysis Reveals CCDC60 As a Potential Biomarker Correlated with Prognosis and Immune Infiltration of Head and Neck Squamous Cell Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 17

PMID 37064086

Authors

Zhixin Liu

Shuai Chen

Wenming Jia

Ye Qian

Xiaoqi Yang

Minfa Zhang

Tianhe Fang

Heng Liu

Affiliations

Soon will be listed here.

Abstract

Background: Coiled-coil domain containing 60 (CCDC60) is a member of the CCDC family, which participates in the progression of many types of cancer. However, the prognostic value of CCDC60 in head and neck squamous cell carcinoma (HNSC) and its function in tumor immunity remain unclear.

Methods: CCDC60 expression and its prognostic potential in HNSC were evaluated by bioinformatics approaches, which was validated in human HNSC samples. Genetic alteration analysis of CCDC60 and the underlying biological function of CCDC60 related co-expressed genes in HNSC were analyzed. The impact of CCDC60 on the regulation of immune infiltration in HNSC was comprehensively investigated. , a series of functional assays on CCDC60 were performed in HNSC cells.

Results: Our study has indicated that compared with the adjacent normal tissues, CCDC60 expression was considerably downregulated in HNSC tissues. High CCDC60 expression was connected with favorable outcome of HNSC patients, and its prognostic significance was examined by distinct clinical characteristics. We identified the CCDC60-related co-expression genes, which were mainly enriched in the NOD-like receptor signaling pathway associated with the inhibition of tumor growth, leading to a better prognosis of HNSC patients. , CCDC60 overexpression significantly inhibited the growth, migration and invasiveness but regulated cell cycle progression, and promoted cell adhesion of Fadu and Cal27 cells. Additionally, high CCDC60 expression had strong connections with the infiltrating levels of immune cells, immune marker sets, immunomodulators and chemokines in HNSC, suggesting that targeting CCDC60 could be a promising strategy to enhance the efficacy of immunotherapy for HNSC patients.

Conclusion: Tumor suppressor CCDC60 may be identified as a prognostic and immune-related indicator in HNSC, which had the potential functions in regulating the immune infiltration of HNSC and improving the response to immunotherapy for HNSC patients.

Citing Articles

Tumor suppressor ACER1 correlates with prognosis and Immune Infiltration in head and neck squamous cell carcinoma.

Liu Z, Yang X, Chen S, Jia W, Qian Y, Zhang M Sci Rep. 2024; 14(1):28039.

PMID: 39543336 PMC: 11564793. DOI: 10.1038/s41598-024-78663-1.

Rare Mutations in CCDC7 Contribute to Early-Onset Preeclampsia by Inhibiting Trophoblast Migration and Invasion.

Tan H, Yu L, Chen J, Wang X, He F, Yu L J Pers Med. 2024; 14(3).

PMID: 38540995 PMC: 10971223. DOI: 10.3390/jpm14030253.

A machine learning model identifies M3-like subtype in AML based on PML/RARα targets.

Shao T, Li J, Su M, Yang C, Ma Y, Lv C iScience. 2024; 27(2):108947.

PMID: 38322990 PMC: 10844831. DOI: 10.1016/j.isci.2024.108947.

A novel coiled-coil domain containing-related gene signature for predicting prognosis and treatment effect of breast cancer.

Wang Y, Wang Y, Zhou J, Ying P, Wang Z, Wu Y J Cancer Res Clin Oncol. 2023; 149(15):14205-14225.

PMID: 37558766 DOI: 10.1007/s00432-023-05222-y.

References

Li Y, Yuan J . Role of deubiquitinating enzymes in DNA double-strand break repair. J Zhejiang Univ Sci B. 2021; 22(1):63-72. PMC: 7818009. DOI: 10.1631/jzus.B2000309. View

Wilson A, Plebanski M, Stephens A . New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators. Curr Med Chem. 2017; 25(36):4758-4784. DOI: 10.2174/0929867324666170830094922. View

Wang C, Stewart R, Kopecek J . Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature. 1999; 397(6718):417-20. DOI: 10.1038/17092. View

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

Zhang D, Qiu X, Li J, Zheng S, Li L, Zhao H . TGF-β secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via miR-34a-VEGF axis. Cell Cycle. 2018; 17(24):2766-2778. PMC: 6343734. DOI: 10.1080/15384101.2018.1556064. View

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. PMC: 3068975. DOI: 10.1186/1471-2105-12-77. View

Leeman J, Li J, Pei X, Venigalla P, Zumsteg Z, Katsoulakis E . Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. JAMA Oncol. 2017; 3(11):1487-1494. PMC: 5710194. DOI: 10.1001/jamaoncol.2017.0973. View

Gao Y, Ouyang Z, Yang C, Song C, Jiang C, Song S . Overcoming T Cell Exhaustion via Immune Checkpoint Modulation with a Dendrimer-Based Hybrid Nanocomplex. Adv Healthc Mater. 2021; 10(19):e2100833. DOI: 10.1002/adhm.202100833. View

10.

Park S, Jang H, Kim M, Kim J, Kwon O, Park J . Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. Carcinogenesis. 2012; 33(8):1494-501. DOI: 10.1093/carcin/bgs178. View

11.

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

12.

Wang H, Luo Q, Feng X, Zhang R, Li J, Chen F . NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma. BMC Cancer. 2018; 18(1):500. PMC: 5930757. DOI: 10.1186/s12885-018-4403-9. View

13.

Qiao X, Jiang J, Pang X, Huang M, Tang Y, Liang X . The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Front Immunol. 2020; 11:1721. PMC: 7531035. DOI: 10.3389/fimmu.2020.01721. View

14.

Song W, Mazzieri R, Yang T, Gobe G . Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition. Front Immunol. 2017; 8:1106. PMC: 5601389. DOI: 10.3389/fimmu.2017.01106. View

15.

Guo L, Li B, Lu Z, Liang H, Yang H, Chen Y . CCDC137 Is a Prognostic Biomarker and Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Analysis. Front Mol Biosci. 2021; 8:674863. PMC: 8155610. DOI: 10.3389/fmolb.2021.674863. View

16.

Geng W, Liang W, Fan Y, Ye Z, Zhang L . Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion. Mol Med Rep. 2017; 17(1):465-473. PMC: 5780142. DOI: 10.3892/mmr.2017.7860. View

17.

Gong Y, Qiu W, Ning X, Yang X, Liu L, Wang Z . CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration. Oncotarget. 2015; 6(28):25856-67. PMC: 4694871. DOI: 10.18632/oncotarget.4624. View

18.

Danaher P, Warren S, Dennis L, DAmico L, White A, Disis M . Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer. 2017; 5:18. PMC: 5319024. DOI: 10.1186/s40425-017-0215-8. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado M . Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007; 99(10):777-89. DOI: 10.1093/jnci/djk179. View